[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hattr-pn\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hattr-pn":48},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100610101",false,"NCT07223203","TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy","TRITON-PN: A Phase 3, Global, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy (hATTR-PN)","TRITON-PN","Inclusion Criteria:\n\n* Has documented diagnosis of hATTR-PN\n* Has a diagnosis of hATTR amyloidosis with polyneuropathy with a documented TTR gene variant\n* Has a neuropathy impairment score (NIS) of 5 to 130 (inclusive)\n* Has a Karnofsky Performance Status (KPS) of ≥60%\n\nExclusion Criteria:\n\n* Has had a liver transplant or is likely, in the opinion of the Investigator, to undergo liver transplantation during the Treatment Period of the study\n* Has known other (non-hATTR) forms of amyloidosis or clinical evidence of leptomeningeal amyloidosis\n* Has a New York Heart Association (NYHA) heart failure classification \\>2\n* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>2.5 upper limit of normal (ULN)\n* Has total bilirubin \\>1.5 ULN\n* Has estimated glomerular filtration rate (eGFR) ≤30 mL\u002Fmin\u002F1.73m\\^2\n* Has other known causes of sensorimotor or autonomic neuropathy","ALL","18 Years","85 Years",{"count":20,"type":21},125,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The purpose of this study is to:\n\n* Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed\n* Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels",[27,28],"Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy","hATTR-PN",[30,31,32,33,34],"Polyneuropathy","Amyloidosis","Transthyretin","TTR","RNAi therapeutic","RECRUITING","2026-06-10",{"date":38,"type":39},"2026-06-12","ACTUAL",{"date":41,"type":39},"2025-12-12",{"date":43,"type":21},"2031-06-12",{"name":45,"class":46},"Alnylam Pharmaceuticals","INDUSTRY",29,""]